kalafatis greece produces 50 of europes oncology drugs 30 of cardio metabolic drugs and 25 of penicillin drugs

The article highlights Greece's significant and growing role in European pharmaceutical production, particularly in oncology, cardio-metabolic, and penicillin drugs. The commercial mechanism is a supply-side capacity expansion: increased domestic production capacity (10 new factories, 14 research centers) and government support (1.5 billion EUR investment) reduce Europe's reliance on non-EU drug imports, potentially lowering input costs for European healthcare systems and improving supply security. The impact is region-specific (Europe/Greece) and affects the pharmaceutical supply chain, with potential margin benefits for Greek producers and cost savings for European buyers. No direct winners/losers are specified beyond the Greek pharmaceutical sector.